MOUD Buprenorphine Sublocade denied as non-formulary by Express Scripts?

Sublocade requires 7+ days sublingual buprenorphine stabilization before LA injectable approved.

Patient-specific justification: prior buprenorphine non-adherence, diversion concerns, work/travel adherence challenges, prior overdose, pregnancy. ASAM NPG OUD 2020. Cite HOFER pivotal (Haight 2019, Lancet). MHPAEA 2024 Final Rule NQTL — demand comparative analysis.

## Why Express Scripts Places Sublocade Off-Formulary — and How to Get It Covered

Express Scripts manages formularies for hundreds of employer and health plan clients, and the specific formulary tier — or formulary exclusion — applied to Sublocade (buprenorphine extended-release subcutaneous injection) varies by plan. Many ESI formularies place Sublocade on a non-preferred or excluded tier, steering members toward sublingual buprenorphine products as the preferred MOUD agent. A non-formulary denial means coverage was refused because the drug is not on the plan's approved drug list, or is on a tier that requires formulary exception approval.

Formulary exceptions are a standard, well-established process — and for Sublocade, which is FDA-approved and included in national MOUD treatment guidelines, they are regularly won with proper documentation.

## Federal Appeal Rights

• Formulary exception request: Before or alongside a formal appeal, submit a formulary exception request under ACA §2719 standards. Plans must have a process for exceptions when a formulary drug is clinically inappropriate or unavailable for the member.
• Internal appeal (ACA §2719 / ERISA §503): File within 180 days of the non-formulary denial. The plan must respond within 30 days (pre-service) or 60 days (post-service).
• Expedited review: Available within 72 hours for urgent clinical situations — appropriate for a patient whose MOUD treatment is being delayed.
• External independent review (ACA §2719): If internal appeal fails, initiate external review within approximately four months of the denial. External reviewers frequently grant formulary exceptions for FDA-approved drugs with documented individual necessity.
• MHPAEA: If non-formulary restrictions on MOUD medications are stricter than comparable medical/surgical restrictions, a parity argument applies.

## The Appeal Process

1. Obtain the plan's formulary exception criteria — these are required to be disclosed. 2. Confirm which formulary applies to the member's specific plan (ESI administers many distinct formularies). 3. File a formulary exception request and a simultaneous or follow-up internal appeal. 4. Request external review if the exception is denied.

## Documentation to Gather

• Diagnosis confirmation: DSM-5 opioid use disorder diagnosis, severity specifier, clinician, and date.
• Preferred-drug trial history: If the formulary requires a trial of the preferred sublingual agent first, document that trial with dates, dose range, clinical outcome, and reason Sublocade is now indicated — or document why the preferred drug is clinically inappropriate for this patient.
• Clinical rationale for Sublocade specifically: Prescriber letter explaining why the non-formulary product is medically necessary for this individual — referencing patient-specific factors and the FDA-approved label and ASAM/SAMHSA guideline framework generically.
• Adverse effect or contraindication documentation: If the preferred agent caused adverse effects or is otherwise not appropriate, document this in chart notes.
• Prescriber credentials: Confirm the prescribing clinician has the required certification or registration to prescribe buprenorphine products.

## Criteria-Mapping Structure

| Formulary Exception Criterion | Supporting Evidence | |---|---| | Preferred formulary drug is clinically inappropriate | [Trial history or contraindication documentation] | | Non-formulary drug is medically necessary | [Prescriber letter with patient-specific rationale] | | Diagnosis confirmed | [Chart notes, DSM-5 criteria] | | Consistent with FDA-approved use | [Prescriber attestation citing label] | | Guideline-supported treatment | [Generic reference to ASAM/SAMHSA protocols] |